Bosentan

證據等級: L5

預測適應症: 9 個

Bosentan: From Pulmonary Arterial Hypertension to Rheumatoid Arthritis

One-Sentence Summary

Bosentan is a dual endothelin receptor antagonist historically used for pulmonary arterial hypertension (PAH) and, per the supporting literature in this evidence pack, systemic sclerosis-related vasculopathy. The TxGNN model's top-ranked prediction is Rheumatoid Arthritis, but the supporting evidence is indirect — the only registered trial actually targets Giant Cell Arteritis, not RA — and is currently backed by 1 clinical trial (wrong indication) and 16 publications, mostly preclinical/review-level. Note: a lower-ranked candidate (limited systemic sclerosis, rank 3) shows a substantially stronger evidence base and is flagged separately below.

Quick Overview

Item	Content
Original Indication	Not available in structured drug data (Data Gap); literature in this evidence pack consistently describes Bosentan as an endothelin receptor antagonist for pulmonary arterial hypertension
Predicted New Indication	Rheumatoid Arthritis
TxGNN Prediction Score	99.80%
Evidence Level	L4
Finland Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (Data Gap DG002). Based on the literature captured in this evidence pack, Bosentan is a dual ETA/ETB endothelin receptor antagonist whose established clinical use is pulmonary arterial hypertension and, in an off-label/extended context, systemic sclerosis-related vasculopathy.

The rationale for a rheumatoid arthritis link is indirect: two preclinical studies show that endothelin signaling contributes to inflammation in collagen-induced and zymosan-induced arthritis mouse models, and that Bosentan can reduce arthritis severity in these models (PMID 22249931, PMID 18515326). This supports a plausible role for endothelin blockade in joint inflammation generally, but it is a mechanistic inference from animal models of arthritis, not RA-specific clinical or translational data.

Importantly, the single clinical trial associated with this prediction (NCT06957002) is not an RA trial — it studies Bosentan in Giant Cell Arteritis, a different rheumatic disease. No RA-specific interventional trial currently exists. Given this gap between the predicted indication and the actual trial population, the evidence level is capped at L4 (mechanism/preclinical only), and this candidate should be treated as an early-stage hypothesis rather than a clinically supported repurposing case.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06957002	Phase 2	Not Yet Recruiting	40	Randomized, controlled trial of Bosentan + glucocorticoids vs. glucocorticoids alone in Giant Cell Arteritis (not RA) — endpoint is failure-free survival at 12 months. Included here because it is the only bosentan trial retrieved under the RA search, but it targets a different disease entity.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
22249931	2012	Preclinical (collagen-induced arthritis)	Inflammation Research	Bosentan ameliorates collagen-induced arthritis in mice; TNF-α induces endothelin system genes
18515326	2008	Preclinical (zymosan-induced arthritis)	Journal of Leukocyte Biology	Endothelins modulate inflammation in zymosan-induced arthritis via LTB4, TNF-α, CXCL-1; ET-1 elevated in RA synovium
19969421	2010	Preclinical (IL-17, antigen-induced arthritis)	Pain	IL-17, a key RA cytokine, drives joint hypernociception in a mouse arthritis model
16766656	2006	Preclinical (IL-15)	PNAS	IL-15-induced hypernociception (relevant to RA) inhibited by a dual ETA/ETB receptor antagonist
20054770	2009	Case Report	Kardiologia Polska	Child with Eisenmenger syndrome and juvenile RA improved clinically on bosentan (given for PAH, not RA)
19851110	2010	Review	Current Opinion in Rheumatology	Overview of rheumatic skin disease pathophysiology and therapy
19487226	2009	Review	Rheumatology (Oxford)	Vasculopathy and PAH in connective tissue disease, including RA
24268012	2014	Review	Rheumatic Diseases Clinics of North America	PAH related to connective tissue disease
18238768	2008	Review	American Journal of Health-System Pharmacy	Drug therapy for systemic sclerosis complications, including endothelin antagonists
21165350	2010	Review	Canadian Respiratory Journal	Treatment of pulmonary hypertension in connective tissue disease with interstitial lung disease

Finland Market Information

Bosentan is currently not marketed in Finland — no product authorizations are on record (0 licenses).

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug interaction data for Bosentan were not available in this evidence pack — Data Gap DG001, flagged as Blocking, and DG002.)

Conclusion and Next Steps

Decision: Hold

Rationale: The rheumatoid arthritis prediction rests on preclinical arthritis-model mechanism data only; the sole associated clinical trial actually targets Giant Cell Arteritis, not RA, so there is no direct clinical evidence for this specific indication. Combined with the Blocking data gap on TFDA/package-insert safety information, this candidate cannot yet clear even an initial safety screen (S1).

To proceed, the following is needed:

TFDA package insert / regulatory safety data (contraindications, warnings, DDI) — currently Blocking (DG001)
Confirmed mechanism of action documentation (DG002)
An RA-specific interventional trial or translational study, since the only registered trial targets a different disease (GCA)
Consider re-prioritizing evaluation resources toward limited systemic sclerosis (rank 3 in this evidence pack), which shows materially stronger evidence — an SSc-matched observational trial, a systematic review/meta-analysis (PMID 36974107), and mechanistic in vitro data on endothelin-driven fibrosis — and is already scored L2/S3 ("Proceed with Guardrails") rather than L4/Hold
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.